A-FIB
MCID: ATR011
MIFTS: 66

Atrial Fibrillation (A-FIB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 36 29 54 6 42 3 44 15 62 62 17 70
Fibrillation, Atrial 39
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
KEGG 36 H00731
ICD9CM 34 427.31
MeSH 44 D001281
NCIt 50 C50466
SNOMED-CT 67 266306001
UMLS 70 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 62 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly. In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should. People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid. AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to congestive heart failure and long qt syndrome 10, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atrial Fibrillation is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Ranolazine and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 42 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Atrial fibrillation, often called AFib or AF, is the most common type of heart arrhythmia. An arrhythmia is when the heart beats too slowly, too fast, or in an irregular way. When a person has AFib, the normal beating in the upper chambers of the heart (the two atria) is irregular, and blood doesn't flow as well as it should from the atria to the lower chambers of the heart (the two ventricles). AFib may occur in brief episodes, or it may be a permanent condition.

KEGG : 36 Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.

Wikipedia : 73 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm (arrhythmia) characterized by the rapid... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 928)
# Related Disease Score Top Affiliating Genes
1 congestive heart failure 32.7 SCN5A NPPB NPPA KCNQ1
2 long qt syndrome 10 32.5 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
3 cardiac arrhythmia 32.3 SCN5A SCN3B SCN1B KCNQ1 KCNH2 KCNE2
4 familial sick sinus syndrome 32.2 SCN5A HCN4
5 short qt syndrome 32.2 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
6 atrial standstill 1 32.1 SCN5A SCN1B NPPB GJA5 ABCC9
7 wolff-parkinson-white syndrome 32.1 SCN5A NPPB KCNQ1 ABCC9
8 familial atrial fibrillation 32.0 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
9 syncope 32.0 SCN5A NPPA KCNQ1 KCNH2
10 ventricular fibrillation, paroxysmal familial, 1 32.0 SCN5A KCNQ1 KCNH2 KCNE2
11 cardiac conduction defect 31.9 SCN5A SCN1B KCNQ1
12 sick sinus syndrome 31.9 SNTA1 SCN5A SCN3B SCN1B NPPA HCN4
13 atrioventricular block 31.9 SCN5A NPPB KCNQ1 KCNH2 KCNE2 HCN4
14 myocardial infarction 31.9 SCN5A NPPB NPPA MYL4 KCNQ1 ABCC9
15 heart disease 31.8 ZFHX3 SCN5A NPPB NPPA MYL4 KCNQ1
16 progressive familial heart block, type ia 31.8 SCN5A GJA5 ANK2
17 atrial heart septal defect 31.8 SCN5A NPPB NPPA HCN4 GJA5
18 cardiac arrhythmia, ankyrin-b-related 31.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
19 patent foramen ovale 31.5 NPPB NPPA GJA5
20 lipoprotein quantitative trait locus 31.5 ZFHX3 SCN5A NPPB NPPA KCNQ1 KCNJ2
21 hypertrophic cardiomyopathy 31.5 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNH2
22 sinoatrial node disease 31.4 SCN5A SCN3B SCN1B KCNQ1 KCNJ2 KCNH2
23 left bundle branch hemiblock 31.4 SCN5A NPPB
24 cardiac arrest 31.4 SCN5A NPPB KCNQ1 KCNH2 HCN4 ANK2
25 aortic valve disease 2 31.2 NPPB NPPA MYL4
26 right bundle branch block 31.1 SCN5A SCN3B SCN2B SCN1B NPPB KCNH2
27 atrial standstill 31.0 SCN5A NPPA GJA5
28 first-degree atrioventricular block 31.0 SCN5A NPPB KCNJ2 KCNH2
29 second-degree atrioventricular block 31.0 SCN5A SCN3B HCN4
30 brugada syndrome 1 30.9 SCN5A KCNH2 KCNA5
31 third-degree atrioventricular block 30.8 SCN5A SCN1B NPPB KCNJ2 KCNH2 HCN4
32 tetralogy of fallot 30.8 SCN5A NPPB NPPA KCNH2 GJA5
33 familial short qt syndrome 30.8 KCNQ1 KCNJ2 KCNH2
34 dilated cardiomyopathy 30.7 SNTA1 SCN5A SCN4B SCN2B NPPB NPPA
35 arrhythmogenic right ventricular cardiomyopathy 30.7 SCN5A NPPB KCNH2 HCN4 ANK2 ABCC9
36 anterolateral myocardial infarction 30.4 NPPB NPPA
37 long qt syndrome 30.4 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
38 progressive familial heart block 30.4 SCN5A SCN1B KCNQ1 KCNH2 HCN4 GJA5
39 ebstein anomaly 30.4 SCN5A HCN4 GJA5
40 familial long qt syndrome 30.3 SNTA1 SCN5A SCN4B KCNQ1 KCNH2 KCNE2
41 brugada syndrome 30.3 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
42 left ventricular noncompaction 30.2 SNTA1 SCN5A SCN3B SCN2B SCN1B KCNQ1
43 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 30.1 SCN5A KCNQ1 KCNJ2 KCNH2 ANK2
44 brugada syndrome 5 30.1 SCN5A SCN1B
45 long qt syndrome 3 29.9 SNTA1 SCN5A SCN4B SCN3B SCN1B KCNQ1
46 catecholaminergic polymorphic ventricular tachycardia 29.9 SNTA1 SCN5A SCN4B SCN3B SCN1B KCNQ1
47 long qt syndrome 1 29.8 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
48 sudden infant death syndrome 29.7 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
49 long qt syndrome 5 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
50 long qt syndrome 6 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.55 MYL4
2 Decreased viability GR00249-S 9.55 ABCC9 GJA5 KCNE2 MYL4 NPPA SCN1B
3 Decreased viability GR00402-S-2 9.55 KCNE2 KCNJ2 KCNQ1 NPPA NUP155 SCN1B

MGI Mouse Phenotypes related to Atrial Fibrillation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2
2 homeostasis/metabolism MP:0005376 10 ABCC9 GJA5 KCNA5 KCNE2 KCNH2 KCNJ2
3 muscle MP:0005369 9.7 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2
4 nervous system MP:0003631 9.36 ABCC9 HCN4 KCNA5 KCNQ1 NUP155 SCN1B

Drugs & Therapeutics for Atrial Fibrillation

PubMed Health treatment related to Atrial Fibrillation: 62

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease . General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9
4
carbamide peroxide Approved Phase 4 124-43-6
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
7
Antazoline Approved Phase 4 91-75-8 2200
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
10
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
11
fluindione Approved, Investigational Phase 4 957-56-2
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
14
Terazosin Approved Phase 4 63590-64-7 5401
15
Quinidine Approved, Investigational Phase 4 56-54-2 441074
16
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
17
Nifedipine Approved Phase 4 21829-25-4 4485
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
23
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Ezetimibe Approved Phase 4 163222-33-1 150311
27
Pantoprazole Approved Phase 4 102625-70-7 4679
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
30
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
31
Amlodipine Approved Phase 4 88150-42-9 2162
32
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
33
Atorvastatin Approved Phase 4 134523-00-5 60823
34
Ticlopidine Approved Phase 4 55142-85-3 5472
35
Liraglutide Approved Phase 4 204656-20-2 44147092
36
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
37
Methohexital Approved Phase 4 151-83-7 9034
38
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
39
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
40
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
41
tannic acid Approved Phase 4 1401-55-4
42
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
43
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
44
Enoxaparin Approved Phase 4 9005-49-6 772
45
Ticagrelor Approved Phase 4 274693-27-5 9871419
46
Verapamil Approved Phase 4 52-53-9 2520
47
Procainamide Approved Phase 4 51-06-9 4913
48
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
49
Digoxin Approved Phase 4 20830-75-5 30322 2724385
50
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 2582)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
2 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
3 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
4 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
5 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
6 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
7 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
8 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
9 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
10 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
11 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
12 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
13 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
14 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
15 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Unknown status NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
16 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
17 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
18 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
19 Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation Unknown status NCT02260206 Phase 4 Colchicine
20 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
21 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
22 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation:a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
23 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
24 A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) Unknown status NCT03536611 Phase 4 dabigatran;warfarin
25 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
26 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
27 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
28 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
29 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
30 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
31 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
32 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
33 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
34 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
35 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
36 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
37 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
38 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
39 Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation Unknown status NCT02673463 Phase 4 Spironolactone;Placebo
40 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
41 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
42 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
43 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
44 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
45 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
46 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
47 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
48 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
49 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
50 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 70 / NDF-RT 51 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

40
Heart, Kidney, Brain, Endothelial, Thyroid, Lung, Liver

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 30662)
# Title Authors PMID Year
1
Effects of corticosteroids on new-onset atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. 61 42
33725992 2021
2
The frequency of gastroesophageal reflux when radiofrequency catheter ablation procedures for atrial fibrillation under general anesthesia with a supraglottic device: Observational pilot study. 61 42
33578560 2021
3
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. 42
33726018 2021
4
Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation. 61 54
20483000 2010
5
Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer. 61 54
19896864 2010
6
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 61 54
20211293 2010
7
Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. 54 61
20170814 2010
8
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. 61 54
20083826 2010
9
[Associations of the genetic polymorphisms in CYP11B2 gene with nonfamilial structural atrial fibrillation]. 61 54
20193392 2009
10
Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic Peptide plasma levels. 61 54
19763191 2009
11
Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation. 54 61
19949577 2009
12
Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. 54 61
19327514 2009
13
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. 61 54
18345329 2008
14
Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. 54 61
17875969 2007
15
Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. 54 61
15851259 2005
16
Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. 54 61
12228786 2002
17
Hypofibrinolysis in atrial fibrillation. 61 54
9842006 1998
18
Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation. 61 54
9489971 1998
19
Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. 54 61
9183333 1997
20
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 61 54
1406859 1992
21
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. 54 61
2183405 1990
22
Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study. 61
33475002 2021
23
Catheter ablation superiority over the pharmacological treatments in atrial fibrillation: a dedicated review. 61
33783271 2021
24
Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. 61
32700579 2021
25
Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. 61
33631081 2021
26
Using 5D flow MRI to decode the effects of rhythm on left atrial 3D flow dynamics in patients with atrial fibrillation. 61
33400296 2021
27
Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. 61
32332235 2021
28
Mindfulness and Interoceptive Exposure Therapy for Anxiety Sensitivity in Atrial Fibrillation: A Pilot Study. 61
31550903 2021
29
No antiarrhythmic effect of direct oral anticoagulants versus vitamin K antagonists in paroxysmal atrial fibrillation patients undergoing catheter ablation. 61
33508338 2021
30
Disparities in atrial fibrillation management: Is race to blame? 61
33524463 2021
31
Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation. 61
33529664 2021
32
Does anticoagulation reduce mortality in patients with atrial fibrillation who later developed a COVID-19 infection? 61
33515615 2021
33
Preoperative Electrocardiogram and Perioperative Methods for Predicting New-Onset Atrial Fibrillation During Lung Surgery. 61
33041171 2021
34
Pericardial adipose tissue: An emerging biomarker of atrial fibrillation? 61
33515617 2021
35
ALDH2 deficiency induces atrial fibrillation through dysregulated cardiac sodium channel and mitochondrial bioenergetics: A multi-omics analysis. 61
33515676 2021
36
Clinical significance of left ventricular reverse remodeling after catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction. 61
33272779 2021
37
Clinical impact of serial change in brain natriuretic peptide before and after catheter ablation in patients with atrial fibrillation and heart failure. 61
33248864 2021
38
Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort. 61
32770310 2021
39
Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. 61
33065765 2021
40
Impact of Baseline Right Bundle Branch Block on Outcomes After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. 61
33385350 2021
41
Short- and medium-term complications after emergency department treatment of patients with atrial fibrillation: design and internal validation of the CoSTuM risk scale. 61
33750048 2021
42
Meta-Analysis of Atrial Fibrillation in Patients With COVID-19. 61
33508269 2021
43
Racial disparities among Asian Americans with atrial fibrillation: An analysis from the NCDR® PINNACLE Registry. 61
33412180 2021
44
Long-term intermittent versus short continuous heart rhythm monitoring for the detection of atrial fibrillation recurrences after catheter ablation. 61
33412184 2021
45
Correction to: Evaluation of Index of Cardio-Electrophysiological Balance in Patients With Atrial Fibrillation on Antiarrhythmic-Drug Therapy. 61
33738017 2021
46
Association of low-voltage areas with the regional wall deformation and the left atrial shape in patients with atrial fibrillation: A proof of concept study. 61
33718586 2021
47
Clinical outcomes of ablation versus non-ablation therapy for atrial fibrillation in Japan: analysis of pooled data from the AF Frontier Ablation Registry and SAKURA AF Registry. 61
33236221 2021
48
New-onset atrial fibrillation in patients with acute kidney injury on continuous renal replacement therapy. 61
33383309 2021
49
Risk of heart failure and prognosis in patients with atrial fibrillation. 61
33388402 2021
50
Catheter ablation for atrial fibrillation in patients with end-stage heart failure and eligibility for heart transplantation. 61
33314690 2021

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 44)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SCN5A NM_198056.2(SCN5A):c.4478A>G (p.Lys1493Arg) SNV Likely pathogenic 67898 rs199473260 GRCh37: 3:38597211-38597211
GRCh38: 3:38555720-38555720
2 SNTA1 NM_003098.2(SNTA1):c.1169C>T (p.Ala390Val) SNV Likely pathogenic 8476 rs121434500 GRCh37: 20:31998009-31998009
GRCh38: 20:33410203-33410203
3 HCN4 NM_005477.3(HCN4):c.2716G>A (p.Gly906Arg) SNV Uncertain significance 404123 rs373572497 GRCh37: 15:73615718-73615718
GRCh38: 15:73323377-73323377
4 SCN5A NM_000335.4(SCN5A):c.414G>A (p.Met138Ile) SNV Uncertain significance 67865 rs199473060 GRCh37: 3:38663959-38663959
GRCh38: 3:38622468-38622468
5 MYH7 , MHRT NM_000257.4(MYH7):c.5190G>T (p.Met1730Ile) SNV Uncertain significance 617741 rs1566522989 GRCh37: 14:23884683-23884683
GRCh38: 14:23415474-23415474
6 TTN-AS1 , TTN NM_001267550.2(TTN):c.73391G>A (p.Arg24464Gln) SNV Uncertain significance 691684 rs750056949 GRCh37: 2:179437468-179437468
GRCh38: 2:178572741-178572741
7 TTN-AS1 , TTN NM_001267550.2(TTN):c.57399A>C (p.Leu19133Phe) SNV Uncertain significance 691692 rs1576219060 GRCh37: 2:179462410-179462410
GRCh38: 2:178597683-178597683
8 NUP155 NM_153485.3(NUP155):c.1348A>G (p.Met450Val) SNV Uncertain significance 977374 GRCh37: 5:37333735-37333735
GRCh38: 5:37333633-37333633
9 NEBL NM_006393.3(NEBL):c.1228-1338del Deletion Uncertain significance 977376 GRCh37: 10:21131116-21131116
GRCh38: 10:20842187-20842187
10 KCNJ2 NM_000891.2(KCNJ2):c.277G>A (p.Val93Ile) SNV Uncertain significance 30121 rs147750704 GRCh37: 17:68171457-68171457
GRCh38: 17:70175316-70175316
11 SCN5A NM_000335.4(SCN5A):c.1282G>A (p.Glu428Lys) SNV Uncertain significance 30048 rs199473111 GRCh37: 3:38647498-38647498
GRCh38: 3:38606007-38606007
12 SCN5A NM_000335.5(SCN5A):c.5958C>A (p.Asn1986Lys) SNV Uncertain significance 30045 rs199473335 GRCh37: 3:38591902-38591902
GRCh38: 3:38550411-38550411
13 SCN5A NM_000335.5(SCN5A):c.5848G>T (p.Val1950Leu) SNV Likely benign 36765 rs41315493 GRCh37: 3:38592012-38592012
GRCh38: 3:38550521-38550521
14 TTN-AS1 , TTN NM_001267550.2(TTN):c.63976C>T (p.His21326Tyr) SNV Likely benign 691743 rs1413306492 GRCh37: 2:179451962-179451962
GRCh38: 2:178587235-178587235
15 TTN-AS1 , TTN NM_001267550.2(TTN):c.57356A>T (p.Lys19119Met) SNV Likely benign 691745 rs1576219870 GRCh37: 2:179462453-179462453
GRCh38: 2:178597726-178597726
16 TTN NM_001267550.2(TTN):c.44014G>A (p.Asp14672Asn) SNV Likely benign 691748 rs1339350914 GRCh37: 2:179495761-179495761
GRCh38: 2:178631034-178631034
17 TTN NM_001267550.2(TTN):c.42513T>A (p.His14171Gln) SNV Likely benign 691749 rs142842339 GRCh37: 2:179498713-179498713
GRCh38: 2:178633986-178633986
18 TTN-AS1 , TTN NM_001267550.2(TTN):c.101212C>T (p.Arg33738Cys) SNV Likely benign 47633 rs56273463 GRCh37: 2:179400130-179400130
GRCh38: 2:178535403-178535403
19 TTN-AS1 , TTN NM_001267550.2(TTN):c.69130C>T (p.Pro23044Ser) SNV Likely benign 47265 rs55980498 GRCh37: 2:179441932-179441932
GRCh38: 2:178577205-178577205
20 TTN , LOC101927055 NM_001267550.2(TTN):c.4359A>T (p.Arg1453Ser) SNV Likely benign 47051 rs376857956 GRCh37: 2:179642552-179642552
GRCh38: 2:178777825-178777825
21 ANK2 NM_001148.6(ANK2):c.9854T>C (p.Ile3285Thr) SNV Benign 190528 rs36210417 GRCh37: 4:114279628-114279628
GRCh38: 4:113358472-113358472
22 AKAP9 NM_005751.4(AKAP9):c.139C>T (p.His47Tyr) SNV Benign 191549 rs35669569 GRCh37: 7:91603115-91603115
GRCh38: 7:91973801-91973801
23 TTN NM_001267550.2(TTN):c.8902+14T>A SNV Benign 137827 rs13388274 GRCh37: 2:179634392-179634392
GRCh38: 2:178769665-178769665
24 TTN-AS1 , TTN NM_001267550.2(TTN):c.87877C>T (p.Arg29293Cys) SNV Benign 47470 rs191482653 GRCh37: 2:179422112-179422112
GRCh38: 2:178557385-178557385
25 KCNH2 NM_000238.4(KCNH2):c.2690A>C (p.Lys897Thr) SNV Benign 67427 rs1805123 GRCh37: 7:150645534-150645534
GRCh38: 7:150948446-150948446
26 BAG3 NM_004281.4(BAG3):c.187C>G (p.Pro63Ala) SNV Benign 178006 rs144041999 GRCh37: 10:121429369-121429369
GRCh38: 10:119669857-119669857
27 BAG3 NM_004281.4(BAG3):c.1138C>T (p.Pro380Ser) SNV Benign 162782 rs144692954 GRCh37: 10:121436204-121436204
GRCh38: 10:119676692-119676692
28 HCN4 NM_005477.3(HCN4):c.2648C>G (p.Pro883Arg) SNV Benign 137542 rs148398509 GRCh37: 15:73615786-73615786
GRCh38: 15:73323445-73323445
29 TTN-AS1 , TTN NM_001267550.2(TTN):c.47315G>A (p.Arg15772Gln) SNV Benign 47010 rs72677233 GRCh37: 2:179482763-179482763
GRCh38: 2:178618036-178618036
30 TTN NM_001267550.2(TTN):c.18776C>G (p.Thr6259Ser) SNV Benign 46644 rs72648949 GRCh37: 2:179594107-179594107
GRCh38: 2:178729380-178729380
31 TTN NM_001267550.2(TTN):c.9359G>A (p.Arg3120Gln) SNV Benign 47636 rs72647894 GRCh37: 2:179632598-179632598
GRCh38: 2:178767871-178767871
32 KCNE2 NM_172201.1(KCNE2):c.269A>G (p.Glu90Gly) SNV not provided 67617 rs199473366 GRCh37: 21:35743046-35743046
GRCh38: 21:34370747-34370747
33 SCN5A NM_000335.4(SCN5A):c.1410C>G (p.Asn470Lys) SNV not provided 30047 rs199473115 GRCh37: 3:38646328-38646328
GRCh38: 3:38604837-38604837
34 KCNQ1 NM_181798.1(KCNQ1):c.59A>G (p.Gln20Arg) SNV not provided 67074 rs199472689 GRCh37: 11:2549211-2549211
GRCh38: 11:2527981-2527981
35 SCN5A NM_198056.2(SCN5A):c.5624T>C (p.Met1875Thr) SNV not provided 68002 rs199473324 GRCh37: 3:38592239-38592239
GRCh38: 3:38550748-38550748
36 KCNQ1 NM_181798.1(KCNQ1):c.37A>G (p.Ser13Gly) SNV not provided 3143 rs120074192 GRCh37: 11:2549189-2549189
GRCh38: 11:2527959-2527959
37 KCNQ1 NM_181798.1(KCNQ1):c.40G>A (p.Val14Met) SNV not provided 67072 rs199472687 GRCh37: 11:2549192-2549192
GRCh38: 11:2527962-2527962
38 KCNQ1 NM_181798.1(KCNQ1):c.244T>C (p.Ser82Pro) SNV not provided 67094 rs199472705 GRCh37: 11:2592575-2592575
GRCh38: 11:2571345-2571345
39 KCNE2 NM_172201.1(KCNE2):c.79C>T (p.Arg27Cys) SNV not provided 6055 rs74315449 GRCh37: 21:35742856-35742856
GRCh38: 21:34370557-34370557
40 SCN5A NM_198056.2(SCN5A):c.1333C>G (p.His44